Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedFeb 25, 2026
DataAggregated Company Financials
Companies62
  • 7D2.1%
  • 3M-14.7%
  • 1Y-5.2%
  • YTD-13.0%

In the last week, the Life Sciences industry is up 2.1%, with Thermo Fisher Scientific up 2.8%. In contrast, the industry has lost 5.2% in the last 12 months. As for the next few years, earnings are expected to grow by 16% per annum.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 25 Feb 2026US$593.7bUS$147.7bUS$13.9b34.1x42.7x4x
Fri, 23 Jan 2026US$710.1bUS$145.8bUS$12.4b36.7x57.4x4.9x
Sun, 21 Dec 2025US$651.7bUS$145.8bUS$12.5b34.7x52.2x4.5x
Tue, 18 Nov 2025US$649.0bUS$145.7bUS$12.2b34.1x53.2x4.5x
Thu, 16 Oct 2025US$615.0bUS$144.3bUS$14.6b32.5x42.3x4.3x
Sat, 13 Sep 2025US$580.3bUS$144.3bUS$14.6b28.6x39.9x4x
Mon, 11 Aug 2025US$550.7bUS$144.2bUS$14.4b28.5x38.2x3.8x
Wed, 09 Jul 2025US$537.0bUS$142.9bUS$9.1b36x58.8x3.8x
Fri, 06 Jun 2025US$514.9bUS$142.9bUS$9.2b34.8x56.2x3.6x
Sun, 04 May 2025US$523.7bUS$142.4bUS$9.7b37.8x54.3x3.7x
Tue, 01 Apr 2025US$575.3bUS$142.5bUS$10.0b37.6x57.8x4x
Thu, 27 Feb 2025US$619.3bUS$143.3bUS$9.8b38.4x63.4x4.3x
Sat, 25 Jan 2025US$702.6bUS$142.4bUS$10.2b45.1x68.8x4.9x
Mon, 23 Dec 2024US$652.4bUS$142.4bUS$10.2b44.3x63.8x4.6x
Wed, 20 Nov 2024US$630.4bUS$142.4bUS$10.4b41.6x60.8x4.4x
Fri, 18 Oct 2024US$725.2bUS$141.8bUS$8.5b37.1x85.4x5.1x
Sun, 15 Sep 2024US$740.7bUS$141.8bUS$8.5b37.5x87.2x5.2x
Tue, 13 Aug 2024US$727.5bUS$141.5bUS$8.5b38.5x85.8x5.1x
Thu, 11 Jul 2024US$662.3bUS$141.3bUS$12.2b39.8x54.4x4.7x
Sat, 08 Jun 2024US$718.4bUS$141.3bUS$12.2b37.7x59x5.1x
Mon, 06 May 2024US$711.4bUS$141.7bUS$12.5b38.9x56.9x5x
Wed, 03 Apr 2024US$737.7bUS$142.0bUS$12.8b43.4x57.7x5.2x
Fri, 01 Mar 2024US$739.0bUS$142.2bUS$12.7b43.8x58x5.2x
Sun, 28 Jan 2024US$698.4bUS$153.8bUS$14.2b35.5x49.3x4.5x
Tue, 26 Dec 2023US$698.8bUS$153.8bUS$14.2b37.5x49.1x4.5x
Thu, 23 Nov 2023US$616.3bUS$153.8bUS$14.0b33.5x44x4x
Sat, 21 Oct 2023US$607.7bUS$154.6bUS$11.2b31.3x54.2x3.9x
Mon, 18 Sep 2023US$697.4bUS$154.6bUS$11.2b33.4x62.2x4.5x
Wed, 16 Aug 2023US$719.3bUS$154.7bUS$11.4b32.4x62.9x4.7x
Fri, 14 Jul 2023US$704.1bUS$155.5bUS$12.7b29.1x55.5x4.5x
Sun, 11 Jun 2023US$680.2bUS$152.4bUS$12.5b29.1x54.4x4.5x
Tue, 09 May 2023US$697.5bUS$152.4bUS$12.9b30.5x54.2x4.6x
Thu, 06 Apr 2023US$722.3bUS$154.6bUS$10.8b26.7x66.9x4.7x
Sat, 04 Mar 2023US$739.7bUS$154.5bUS$10.9b31x68x4.8x
Price to Earnings Ratio

68x


Total Market Cap: US$739.7bTotal Earnings: US$10.9bTotal Revenue: US$154.5bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 58.5x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 42.7x which is lower than its 3-year average PE of 58.5x.
  • The 3-year average PS ratio of 4.5x is higher than the industry's current PS ratio of 4.0x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 8.5% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.50%
Healthcare0.72%
Life Sciences2.12%
Clinical Research and Equipment2.12%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TMO Thermo Fisher ScientificUS$515.602.8%
+US$5.3b		-4.4%PE28.9x
DHR DanaherUS$209.191.4%
+US$2.0b		-0.6%PE41.1x
ICLR ICONUS$104.0917.5%
+US$1.2b		-47.3%PE13.3x
ILMN IlluminaUS$122.905.5%
+US$977.0m		28.3%PE22.1x
TEM Tempus AIUS$57.9510.3%
+US$958.9m		-1.9%PS9.3x

Latest News

TEM
US$57.95
Tempus AI
7D
10.3%
1Y
-1.9%
DHR
US$209.19
Danaher
7D
1.4%
1Y
-0.6%
ILMN
US$122.90
Illumina
7D
5.5%
1Y
28.3%
SHC
US$16.72
Sotera Health
7D
-2.2%
1Y
21.8%

SHC: Organic Investment And Deleveraging Will Support Future Upside Potential

Analysts have kept their Sotera Health price target effectively unchanged at about $20.44, reflecting minimal updates to assumptions around the discount rate, long term revenue growth, profit margins, and future P/E expectations. What's in the News Sotera Health signaled that its primary use of capital remains focused on organic growth, with management highlighting continued investment to strengthen existing businesses.
RGEN
US$134.67
Repligen
7D
-2.5%
1Y
-17.3%

RGEN: M&A Focus And New Bioprocessing Resins Will Drive Future Upside

Analysts have raised their Repligen price target by $10 to $190.89, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E as reflected in recent Street research. Analyst Commentary Bullish Takeaways Bullish analysts see the higher US$190.89 price target as better aligned with updated assumptions for discount rates and future P/E, suggesting the shares may not fully reflect their revised valuation framework.
ICLR
US$104.09
ICON
7D
17.5%
1Y
-47.3%

ICLR: Oncology Expansion And Accounting Overhang Are Expected To Reset Sentiment

Analysts have lowered their average price target on ICON from about $206 to roughly $155 as they factor in the ongoing internal accounting investigation, modestly softer growth and margin assumptions, a slightly higher discount rate, and a reduced future P/E multiple, even as some describe the recent share price weakness as creating a more compelling entry point. Analyst Commentary Recent research on ICON reflects a split view, with some analysts turning more constructive after the share price pullback while others remain cautious given the internal accounting investigation and softer growth and margin assumptions.
MTD
US$1,379.66
Mettler-Toledo International
7D
2.0%
1Y
5.4%
TECH
US$57.60
Bio-Techne
7D
-1.5%
1Y
-10.3%

TECH: Multiomic Platforms And 3D Workflows Will Support A Steady Forward Outlook

Narrative Update on Bio-Techne Analysts have adjusted their price target on Bio-Techne from $70.00 to $75.25, citing updated assumptions for revenue growth, profit margin, discount rate and future P/E that collectively support a higher assessed fair value. What’s in the News Ella benchtop immunoassay platform received CE-IVD marking and is now available for clinical use in the European Union.
WAT
US$326.30
Waters
7D
1.5%
1Y
-14.3%

WAT: Reorganization And Margin Pressure Will Likely Cap Upside For Now

Analysts now mark their price target for Waters at $330, down from $349, citing updated assumptions around revenue growth, profit margins, discount rate, and future P/E that change their overall valuation framework. What's in the News Waters closed a transaction and reorganized into four divisions focused on high-volume testing and adjacent markets, now grouped as Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials Sciences (company announcement).
STVN
US$15.42
Stevanato Group
7D
-3.4%
1Y
-26.1%
TMO
US$515.60
Thermo Fisher Scientific
7D
2.8%
1Y
-4.4%

TMO: 2026 Tools Recovery And AI Partnerships Will Drive Earnings Power

Thermo Fisher Scientific's analyst price targets have moved higher by up to $117 per share, as analysts broadly lift their outlook on the company, citing refined growth and margin assumptions along with a series of recent target increases across the Street. Analyst Commentary Bullish analysts are largely aligned in lifting price targets for Thermo Fisher Scientific, pointing to what they see as an improving setup into 2026 and a company that is executing against refined growth and margin assumptions.
MEDP
US$442.20
Medpace Holdings
7D
3.3%
1Y
29.7%
PSNL
US$8.29
Personalis
7D
-3.3%
1Y
96.0%

PSNL: Medicare Coverage And Refined Assumptions Will Support A Brighter Outlook

Analysts have increased their price target on Personalis by $1, citing updated views on fair value, slightly revised discount rate assumptions, and refreshed expectations for revenue growth, profit margin, and future P/E. Analyst Commentary Although the latest research includes a higher price target for Personalis, the tone around the stock remains measured.
CYRX
US$8.27
Cryoport
7D
-2.4%
1Y
36.7%

CYRX: New Cryogenic Freezer Platform Will Support Long Term Margin Prospects

Analysts have made a small trim to their $9.50 price target on Cryoport, reflecting slightly adjusted assumptions around the discount rate, revenue growth, profit margin, and future P/E, while keeping their fair value view broadly intact. What's in the News Cryoport launched the MVE Fusion 800 Series, a self sustaining cryogenic freezer that removes the need for a continuous liquid nitrogen supply, aiming to provide reliability, safety, and energy efficiency in a compact format suitable for space constrained labs and facilities (Key Developments).
AZTA
US$28.18
Azenta
7D
-1.6%
1Y
-39.9%

AZTA: 2026 Margin Framework And Buybacks Will Support Future Upside

Analysts have trimmed their average price target on Azenta from about $43.50 to roughly $38.67, reflecting recent target cuts of $5 and $9, along with updated views on revenue growth, margins and a lower future P/E assumption. Analyst Commentary Recent research shows a mixed but detailed set of views around Azenta, with some focusing on long term growth potential and others dialing back expectations on valuation and near term execution.
QGEN
US$48.50
Qiagen
7D
-0.5%
1Y
16.1%

QGEN: Fairly Valued Outlook Will Hinge On Possible Sale And Execution Risks

Qiagen's analyst price target has edged up by about $1 to roughly $55, as analysts factor in slightly higher fair value and profit margin assumptions, along with a modest adjustment to growth expectations and P/E multiples. Analyst Commentary Recent Street research on Qiagen has been active, with several firms adjusting price targets in both directions and a few issuing downgrades.